143 related articles for article (PubMed ID: 3397998)
1. Deletion sequences of salmon calcitonin that retain the essential biological and conformational features of the intact molecule.
Epand RM; Epand RF; Stafford AR; Orlowski RC
J Med Chem; 1988 Aug; 31(8):1595-8. PubMed ID: 3397998
[TBL] [Abstract][Full Text] [Related]
2. Biologically potent analogues of salmon calcitonin which do not contain an N-terminal disulfide-bridged ring structure.
Orlowski RC; Epand RM; Stafford AR
Eur J Biochem; 1987 Jan; 162(2):399-402. PubMed ID: 3803393
[TBL] [Abstract][Full Text] [Related]
3. Conformational and biological properties of partial sequences of salmon calcitonin.
Epand RM; Stahl GL; Orlowski RC
Int J Pept Protein Res; 1986 May; 27(5):501-7. PubMed ID: 3733320
[TBL] [Abstract][Full Text] [Related]
4. des-Ser2 salmon calcitonin: a biologically potent synthetic analog.
Schwartz KE; Orlowski RC; Marcus R
Endocrinology; 1981 Mar; 108(3):831-5. PubMed ID: 6257497
[TBL] [Abstract][Full Text] [Related]
5. Conformational flexibility and biological activity of salmon calcitonin.
Epand RM; Epand RF; Orlowski RC; Seyler JK; Colescott RL
Biochemistry; 1986 Apr; 25(8):1964-8. PubMed ID: 3707923
[TBL] [Abstract][Full Text] [Related]
6. A noncyclical analog of salmon calcitonin (N alpha-propionyl Di-Ala1,7,des-Leu19 sCT) retains full potency without inducing anorexia in rats.
Yates AJ; Gutierrez GE; Garrett IR; Mencel JJ; Nuss GW; Schreiber AB; Mundy GR
Endocrinology; 1990 Jun; 126(6):2845-9. PubMed ID: 2351097
[TBL] [Abstract][Full Text] [Related]
7. Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation.
Houssami S; Findlay DM; Brady CL; Martin TJ; Epand RM; Moore EE; Murayama E; Tamura T; Orlowski RC; Sexton PM
Mol Pharmacol; 1995 Apr; 47(4):798-809. PubMed ID: 7723741
[TBL] [Abstract][Full Text] [Related]
8. The hydrophobic moment of the amphipathic helix of salmon calcitonin and biological potency.
Epand RM; Seyler JK; Orlowski RC
Eur J Biochem; 1986 Aug; 159(1):125-7. PubMed ID: 3743567
[TBL] [Abstract][Full Text] [Related]
9. Analogue separates biological effects of salmon calcitonin on brain and renal cortical membranes.
Twery MJ; Seitz PK; Nickols GA; Cooper CW; Gallagher JP; Orlowski RC
Eur J Pharmacol; 1988 Oct; 155(3):285-92. PubMed ID: 3266153
[TBL] [Abstract][Full Text] [Related]
10. Determinants for calcitonin analog interaction with the calcitonin receptor N-terminus and transmembrane-loop regions.
Stroop SD; Nakamuta H; Kuestner RE; Moore EE; Epand RM
Endocrinology; 1996 Nov; 137(11):4752-6. PubMed ID: 8895343
[TBL] [Abstract][Full Text] [Related]
11. Structural and conformational requirements for human calcitonin activity: design, synthesis, and study of lactam-bridged analogues.
Kapurniotu A; Taylor JW
J Med Chem; 1995 Mar; 38(5):836-47. PubMed ID: 7877149
[TBL] [Abstract][Full Text] [Related]
12. The biological potency of a series of analogues of human calcitonin correlates with their interactions with phospholipids.
Epand RF; Orlowski RC; Epand RM
Biopolymers; 2004; 76(3):258-65. PubMed ID: 15148685
[TBL] [Abstract][Full Text] [Related]
13. Biologically active calcitonin analogs which have minimal interactions with phospholipids.
Epand RM; Epand RF; Orlowski RC
Biochem Biophys Res Commun; 1988 Apr; 152(1):203-7. PubMed ID: 3358761
[TBL] [Abstract][Full Text] [Related]
14. Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept for potent calcitonin analogues.
Taylor JW; Jin QK; Sbacchi M; Wang L; Belfiore P; Garnier M; Kazantzis A; Kapurniotu A; Zaratin PF; Scheideler MA
J Med Chem; 2002 Feb; 45(5):1108-21. PubMed ID: 11855991
[TBL] [Abstract][Full Text] [Related]
15. Presence of an amphipathic helical segment and its relationship to biological potency of calcitonin analogs.
Epand RM; Epand RF; Orlowski RC
Int J Pept Protein Res; 1985 Jan; 25(1):105-11. PubMed ID: 3880517
[TBL] [Abstract][Full Text] [Related]
16. Conformational requirements for activity of salmon calcitonin.
Findlay DM; Michelangeli VP; Martin TJ; Orlowski RC; Seyler JK
Endocrinology; 1985 Sep; 117(3):801-5. PubMed ID: 4017965
[TBL] [Abstract][Full Text] [Related]
17. Stable human calcitonin analogues with high potency on bone together with reduced anorectic and renal actions.
Uda K; Kobayashi Y; Hisada T; Orlowski RC; Bastian JW; Arnaud CD; Wakabayashi K
Biol Pharm Bull; 1999 Mar; 22(3):244-52. PubMed ID: 10220278
[TBL] [Abstract][Full Text] [Related]
18. Biological activities and receptor interactions of des-Leu16 salmon and des-Phe16 human calcitonin.
Findlay DM; Michelangeli VP; Orlowski RC; Martin TJ
Endocrinology; 1983 Apr; 112(4):1288-91. PubMed ID: 6299689
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and characterization of a model peptide having potent calcitonin-like biological activity: implications for calcitonin structure/activity.
Moe GR; Kaiser ET
Biochemistry; 1985 Apr; 24(8):1971-6. PubMed ID: 2990546
[TBL] [Abstract][Full Text] [Related]
20. Structure-function studies of analogues of parathyroid hormone (PTH)-1-34 containing beta-amino acid residues in positions 11-13.
Peggion E; Mammi S; Schievano E; Silvestri L; Schiebler L; Bisello A; Rosenblatt M; Chorev M
Biochemistry; 2002 Jun; 41(25):8162-75. PubMed ID: 12069609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
